

Mahajan, Vinay

From: Communications, Novartis (Gen)
Sent: Tuesday, July 18, 2017 11:35 AM
To: Mahajan, Vinay
Subject: Letter to associates from Joe Jimenez: Novartis Leadership Announcement - July 2017



Novartis Leadership Announcement

July 18, 2017

[Read announcement in German](#) (PDF)

Dear Associates,

I am pleased to make the following leadership announcements. The mix of internal and external talent brings diverse experiences and backgrounds to our team that will further strengthen our external focus and innovation power.

Following a diverse and distinguished career at Novartis, **Jürgen Brokatzky-Geiger**, *Global Head, Corporate Responsibility*, will retire effective October 31, 2017, after reaching his Swiss legal retirement age. Jürgen joined the company in 1983 as Laboratory Head in Process R&D, and worked in a variety of roles of increasing responsibility, including Global Head of Technical R&D, Novartis Pharmaceuticals. In 2003, he became a member of the Executive Committee of Novartis (ECN) as Global Head, Human Resources, and focused on building a global HR function. In 2014, he was appointed to his current role, where he developed an integrated Corporate Responsibility strategy, centered on “access to healthcare” and “doing business responsibly”. I would like to thank Jürgen for his many significant contributions to our

company over his 34 years of service.

Effective October 1, 2017, **Patrice Matchaba, M.D.**, will succeed Jürgen as *Global Head, Corporate Responsibility*, reporting to me. After practicing as a medical doctor and scientific researcher in South Africa, Patrice joined Novartis in 2000, leading specialized areas in Clinical Development based in the US. Over the past 17 years, he has held roles of increasing responsibility in Global Drug Development and is currently Head of the Cardio-Metabolic Development Unit. Patrice is a passionate advocate of Corporate Responsibility, and brings strong professional and clinical experience to the role. His successor will be announced in due course.

Pharmaceuticals

Paul Spittle is appointed *Global Head of Strategy, Novartis Pharmaceuticals*, effective August 1, 2017, reporting to Paul Hudson, CEO Novartis Pharmaceuticals. Paul is joining us from AstraZeneca, where he most recently served as Country President of Australia & New Zealand. He succeeds Chinmay Bhatt, who will assume the role of *CPO Head, Austria*, effective August 1, 2017.

Oncology

Effective June 1, 2017, **Myriam Mendila** was appointed *Chief Medical Officer, Oncology*, reporting to Bruno Strigini, CEO Novartis Oncology. Myriam joined us from Genentech, where she most recently held the position of Head, US Medical Affairs, and Regional Medical Director, North America. Prior to that, she was Head, Global Medical Affairs, Product Development at Roche.

Sandoz

Gabriel Morelli was appointed to the newly created position of *Global Head, Commercial Excellence, Sandoz*, reporting to Richard Francis, CEO Sandoz, effective July 1, 2017. Gabriel joined Novartis in 2015 as Head Strategy, Anti-Infectives & API, Sandoz. Most recently, he was Head, Divisional Strategy, Sandoz, *ad interim*.

Effective July 1, 2017, **Christian Pawlu** succeeded Gabriel Morelli as *Head, Divisional*

Strategy, Sandoz, reporting to Richard Francis. In this new role, Christian will lead the overarching strategy development for the division. He joins us from Crystalline Mirror Solutions (CMS), an Austrian/US high-tech company, where he was the CEO. Christian previously worked as Partner at McKinsey with a focus on generics markets.

Alcon

Rajkumar (Raj) Narayanan was appointed *Region President Asia, Alcon*, reporting to David Endicott, President Commercial & Innovation, Alcon, effective June 1, 2017. Raj joined us from Allergan, where he worked in a number of leadership positions, most recently as Senior Vice President and President, Asia Pacific. He succeeded **Eric Van Oppens**.

Effective July 1, 2017, **Eric Van Oppens** assumed the role of *Head, Global Strategic Initiatives, Alcon*, reporting to Mike Ball, CEO Alcon. In this new role, Eric will drive a series of critical initiatives aimed at creating a more agile and sustainable operating model. He continues to be a member of Alcon's Executive Leadership Team. Eric joined Novartis in 2005 as Head, North Africa Cluster, Pharmaceuticals, and has since held commercial, regional and country leadership roles across Asia.

Novartis Institutes for BioMedical Research (NIBR)

Vishal Patel, PhD was appointed *Chief of Staff, NIBR*, reporting to James (Jay) Bradner, M.D., President, NIBR, effective May 22, 2017. Vishal joins Novartis from Merck KGaA, where he held the position of Senior Director for Global External Affairs.

Effective July 1, 2017, **Revathi Rammohan** was appointed *Chief Financial Officer (CFO), NIBR*, reporting operationally to Jay Bradner and functionally to Harry Kirsch, Chief Financial Officer, Novartis. Revathi joined Novartis in 1985 in Finance in India. She has since held Finance positions of increasing responsibility in South Africa, Europe and the US. Revathi most recently served as CFO for Novartis Business Services (NBS).

Scott Brown, Vice President and General Counsel, NIBR, will be appointed *Chief Administrative Officer (CAO), NIBR*, reporting to Jay Bradner, effective October 1, 2017. In this new role, he will oversee Scientific Operations, Communications and Informatics,

in addition to his current responsibilities for NIBR's Legal and Patents teams.

Global Drug Development (GDD)

Effective June 1, 2017, **Tohru Hirose** was appointed *Head of Japan Development*, reporting operationally to Vas Narasimhan, M.D., Head, Global Drug Development and Chief Medical Officer, and administratively to Kazunari Tsunaba, President of Novartis Pharma, Japan. Hirose-san joined Novartis in 2004 as Head of Project Management, Japan, and he most recently held the position of Head, Pharma Development, Japan.

Novartis International

Anja König will be appointed *Head, Novartis Venture Fund*, reporting to Harry Kirsch, effective September 1, 2017. Anja joined Novartis in 2006 as Assistant to the Chairman and CEO, Novartis. Most recently, she held the position of Managing Director, Novartis Venture Fund. She succeeds **Reinhard Ambros**, who decided to retire after more than 21 years of service at Novartis, including 12 years leading the Novartis Venture Fund. I want to thank Reinhard for his significant contributions during his career at Novartis.

Effective May 1, 2017, **Alejandro Castro Delgado** was appointed *Regional Head Internal Audit, APAC*, reporting to Peter Elam, Head of Internal Audit, Novartis. Alejandro joined the company in 2009 as Audit Manager, Latin America. Most recently, he held the position of Audit Manager in the APAC team, and Regional Head Internal Audit, APAC, *ad interim* since October 2016. Alejandro succeeds **Ross Cattell**, who assumed the role of *Head of Science and Technology Audit*, reporting to Peter Elam, effective September 1, 2016.

Chris Klee, CFO, NIBR, will take over the full-time position of dedicated *US Country CFO, Novartis*, expanding his current role as US CCFO, effective October 1, 2017. Chris will report operationally to Tom Kendris, President Novartis US, and functionally to Harry Kirsch. Chris continues to be a member of the Novartis Finance Leadership Team.

Please join me in congratulating these leaders and in wishing them success in their new roles.

Best regards,

Joe Jimenez

